Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1
Nature - The phase 1b NIVIPIT trial shows that in combined therapy with intravenous nivolumab (anti-PD1), intratumoural administration of ipilimumab (anti-CTLA4) offers improved safety and greater...
nature.com